Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
283 hedge funds and large institutions have $7B invested in Apellis Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 64 funds opening new positions, 79 increasing their positions, 110 reducing their positions, and 33 closing their positions.
186% more call options, than puts
Call options by funds: $379M | Put options by funds: $133M
94% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 33
61% more capital invested
Capital invested by funds: $4.34B → $7B (+$2.66B)
11% more funds holding
Funds holding: 256 → 283 (+27)
1.91% more ownership
Funds ownership: 96.75% → 98.66% (+1.9%)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
28% less repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 110
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$233M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$64.8M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$56.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$34.3M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
+$31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Slate Path Capital
New York
|
-$78.7M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$69.8M |
| 3 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
-$33.5M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$25M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$20.9M |
APLS Hedge Fund Activity: Q4 2023 in Review
283 of the 6,864 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q4 2023, worth a combined $7B — up 61% from $4.34B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new APLS positions and 33 closed out — a net gain of 31 holders — while 79 added to existing stakes and 110 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $233M. The largest seller was Slate Path Capital, exiting entirely with an estimated $78.7M sold.
- 283 institutional investors held Apellis Pharmaceuticals (APLS) as of Q4 2023, up from 256 in Q3 2023.
- Funds reported $7B of Apellis Pharmaceuticals stock for Q4 2023, up 61% quarter-over-quarter.
- 64 funds opened new Apellis Pharmaceuticals positions in Q4 2023 and 33 closed out, a net change of +31 holders.
- The largest Apellis Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $233M added.
- The largest Apellis Pharmaceuticals seller in Q4 2023 was Slate Path Capital, an estimated $78.7M sold.
Based on aggregated 13F filings for Q4 2023.